Recent advances in insulin technology highlighted at the EASD meeting demonstrate a shift towards personalised, convenient, and rapid-acting treatments, with new formulations and delivery methods aiming to enhance daily diabetes management.
At this year’s European Association for the Study of Diabetes meeting, the discussion around insulin was less about a single breakthrough than about a series of small but potentially important advances. A review in Diabetes Technology & Therapeutics by Torben Biester, Julia K. Mader and Lutz Heinemann, highlighted in the redGDPS blog, points to a field that is becoming more diversified, with new formulations, biosimilars and delivery approaches all competing to improve day-to-day diabetes care. The broader message is that insulin is no longer being developed only as a basic glucose-lowering drug, but as part of a more tailored treatment toolkit for people living with diabetes.
Among the most eye-catching developments is AT278, a highly concentrated insulin aspart formulation studied in people with type 2 diabetes and reported in Diabetes, Obesity and Metabolism. Researchers including Enrique Carretero Anibarro found that the 500 U/mL formulation produced ultra-rapid action regardless of body mass index, a finding that may matter for patients in whom speed of absorption and dose volume both affect usability. If confirmed in broader studies, that kind of profile could help address one of the long-standing frustrations in insulin therapy: the gap between a laboratory formulation and how quickly and predictably it works in real patients.
The wider insulin conversation at EASD also reflects how much attention is being paid to timing, convenience and individualisation. A systematic review and network meta-analysis published in Diabetes, Obesity and Metabolism compared once-weekly and once-daily basal insulins in type 1 diabetes, underscoring the continuing search for regimens that preserve control while reducing treatment burden. At the same time, a position statement from the EASD and ADA Diabetes Technology Working Group argued that diabetes technology must be adapted to the person, not the other way round, reinforcing the idea that the best insulin strategy is increasingly one that fits an individual’s routines, risks and preferences.
These developments are unfolding alongside updated guidance from the American Diabetes Association and EASD. A 2026 consensus report on type 2 diabetes and a separate correction to the 2026 adult type 1 diabetes report, both published in Diabetologia, show how quickly the evidence base is moving and how closely clinical recommendations are being tied to new data. For clinicians, the practical challenge is not simply choosing a newer insulin, but deciding where each product genuinely adds value over established options, and whether the promise of greater precision, fewer injections or easier use survives contact with everyday care.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
